Headquartered in Austin, Natera is one of the largest and fastest-growing precision diagnostics companies in the world — and a defining Texas life-sciences success story. From its early beginnings in California, the company relocated to Austin and has since scaled into a global enterprise with more than 6,000 employees worldwide.

Today, Natera operates approximately 300,000 square feet of advanced laboratory and office facilities in Austin and is redefining how cancer is detected, monitored, and treated. Its flagship oncology test, Signatera™, has fundamentally changed clinical practice by enabling the detection of molecular residual disease through a test personalized to each patient.

Used by more than half of U.S. oncologists, Signatera can identify cancer recurrence and treatment response months to years before conventional imaging, allowing physicians to intervene earlier and tailor therapy with greater precision. The company holds more than 500 issued and pending patents, and its tests are supported by more than 325 peer-reviewed publications. Natera’s technologies are further validated through extensive clinical evidence, large-scale clinical trials, and deep partnerships with academic medical centers, health systems, and biopharmaceutical innovators worldwide.

Texas has been instrumental to Natera’s success. Early collaboration with MD Anderson helped drive national reimbursement coverage of Signatera by Medicare. Austin’s deep STEM talent pool, proximity to leading research institutions, and pro-growth business environment have enabled the company to scale at a pace rarely seen in healthcare.

In turn, Natera has become a cornerstone of Texas’s rapidly emerging life-sciences ecosystem — demonstrating that world-leading diagnostics innovation can be built, scaled, and led from Texas.

As Natera continues its expansion nationally and globally, the company remains firmly committed to Texas as its home — driving high-value job creation, advancing cancer care, and reinforcing Texas’s position as a premier destination for life-sciences innovation.